Singular Genomics Systems, Inc, a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today unveiled the G4X™ Spatial Sequencer. The G4X is designed to offer high-throughput in situ direct sequencing of RNA (Direct-Seq™), targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (FFPE) tissues. The G4X will share the same platform as the existing G4® sequencer and is expected to be the industry’s first dual-purpose instrument offering both traditional NGS and tissue-based spatial sequencing capabilities. With the addition of high-throughput multiomics and novel Direct-Seq technology to its portfolio with the G4X, Singular is positioned to become the only company worldwide to offer in situ spatial sequencing of tissues and NGS on the same instrument.
The G4X Spatial Sequencer is designed to offer novel capabilities, stackable data streams, and unprecedented throughput for spatial profiling of tissue. Its novel capabilities will include Direct-Seq, which is the sequencing of RNA molecules in situ and has the potential to open new areas of scientific discovery. In addition, the G4X will offer readouts of targeted transcripts, targeted proteins, and a fluorescent H&E stain, all in the same tissue sample. And lastly, this combination of readout modalities will be offered at an unprecedented scale. With 40 cm2 of flexible imaging area and single-day run times, the G4X system will enable labs to process 20 times more samples per week than existing technologies.
“We founded Singular with a commitment to listen to our customers, to innovate, and to bring products to market that have an impact,” stated Drew Spaventa, co-founder and Chief Executive Officer of Singular Genomics. “The G4X embodies this commitment by providing new capabilities, novel data streams, and scale. This powerful combination has the potential to open new areas of discovery, accelerate research, and advance the medical field.”
Initial kits on the G4X will support transcription, proteomics, and offer a fluorescent H&E stain. The system is designed to accommodate a large number of samples and will read out hundreds of gene targets and dozens of proteins in the same tissue section. Content will be available in fixed panels or customizable for the customer. Future kits on the G4X will also support Direct-Seq, which is designed to directly read variable regions of RNA, such as cancer hotspot mutations, guide RNAs in CRISPR screens, or B- and T-cell receptor sequences. The capability to perform direct sequencing of RNA within cells and tissues is expected to bring a powerful new readout modality for in situ molecular pathology. Direct-Seq will be initially available as a service, with plans for broader release shortly thereafter.
SOURCE: Globenewswire